Qtron Investments LLC Cuts Stake in AbbVie Inc. $ABBV

Qtron Investments LLC reduced its stake in shares of AbbVie Inc. (NYSE:ABBV) by 12.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,065 shares of the company’s stock after selling 2,854 shares during the period. AbbVie accounts for about 0.6% of Qtron Investments LLC’s investment portfolio, making the stock its 23rd largest position. Qtron Investments LLC’s holdings in AbbVie were worth $4,585,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently bought and sold shares of ABBV. Eclectic Associates Inc. ADV boosted its holdings in AbbVie by 0.8% in the fourth quarter. Eclectic Associates Inc. ADV now owns 5,852 shares of the company’s stock valued at $1,337,000 after acquiring an additional 45 shares during the last quarter. Weil Company Inc. boosted its holdings in AbbVie by 2.3% in the third quarter. Weil Company Inc. now owns 2,026 shares of the company’s stock valued at $469,000 after acquiring an additional 46 shares during the last quarter. Hardin Capital Partners LLC boosted its holdings in AbbVie by 1.4% in the fourth quarter. Hardin Capital Partners LLC now owns 3,321 shares of the company’s stock valued at $759,000 after acquiring an additional 46 shares during the last quarter. Dogwood Wealth Management LLC boosted its holdings in AbbVie by 10.8% in the fourth quarter. Dogwood Wealth Management LLC now owns 473 shares of the company’s stock valued at $108,000 after acquiring an additional 46 shares during the last quarter. Finally, Quantum Private Wealth LLC boosted its holdings in AbbVie by 2.0% in the fourth quarter. Quantum Private Wealth LLC now owns 2,376 shares of the company’s stock valued at $543,000 after acquiring an additional 46 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Trading Up 0.0%

Shares of ABBV opened at $225.04 on Friday. AbbVie Inc. has a 1 year low of $181.73 and a 1 year high of $244.81. The stock has a market cap of $397.60 billion, a P/E ratio of 110.86, a price-to-earnings-growth ratio of 0.69 and a beta of 0.32. The stock’s 50-day moving average price is $210.80 and its two-hundred day moving average price is $219.01.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm had revenue of $15 billion for the quarter, compared to analysts’ expectations of $14.72 billion. During the same quarter last year, the business earned $2.46 earnings per share. The company’s revenue was up 12.4% compared to the same quarter last year. As a group, equities analysts forecast that AbbVie Inc. will post 14.3 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Morgan Stanley raised their price target on AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a report on Monday. DZ Bank upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. Piper Sandler raised their target price on AbbVie from $294.00 to $298.00 and gave the stock an “overweight” rating in a report on Thursday, May 14th. Finally, Evercore set a $235.00 target price on AbbVie in a report on Friday, May 15th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.43.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Analysts and media coverage highlighted AbbVie’s Skyrizi and Rinvoq as key growth drivers, noting strong first-quarter performance and the potential for continued sales momentum through 2026, including additional indications. Will Skyrizi & Rinvoq Continue to Drive AbbVie’s Topline Through 2026?
• Positive Sentiment: Another market commentary framed AbbVie as a growth-pharma stock at a value-pharma price, reinforcing the view that its earnings growth and pipeline may justify the valuation. AbbVie: Growth-Pharma Profile At A Value-Pharma Price
• Positive Sentiment: AbbVie was also featured on CNBC’s “Final Trades”, which can support investor sentiment by keeping the stock in the market spotlight. AbbVie, Devon Energy and more on CNBC’s ‘Final Trades’
• Neutral Sentiment: Several pieces described AbbVie as a stock worth watching or holding after a strong run, with valuation and balance-sheet concerns tempering enthusiasm but not signaling a major change in the business outlook. Up 45% Since 2024: 1 Glaring Reality That Makes AbbVie Stock a Hold at $225
• Negative Sentiment: AbbVie also faced a FDA Complete Response Letter for its fast-acting neurotoxin TrenibotE, citing manufacturing-related issues. While the letter reportedly raised no safety or efficacy concerns, it delays the program and adds near-term regulatory uncertainty. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.